Adimmune Corp (4142) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.073x

Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million ≈ $-11.19 Million USD) by net assets (NT$4.85 Billion ≈ $152.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Adimmune Corp for the company's overall valuation and market capitalisation.

Adimmune Corp - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Adimmune Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency. Explore Adimmune Corp (4142) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Astral Resources NL AU:AAR	-0.011x
Illumination Acquisition Corp I Class A Ordinary Shares NASDAQ:ILLU	N/A
High Tide Inc V:HITI	0.043x
Hyundai Cement KO:006390	0.059x
Jaya Tiasa Holdings Bhd KLSE:4383	0.046x
Warriedar Resources Ltd AU:WA8	0.016x
Transimex Saigon Corp VN:TMS	0.016x
Metropolitan Land Tbk JK:MTLA	0.010x

Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)

The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024. View 4142 live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.56 Billion ≈ $175.22 Million	NT$668.48 Million ≈ $21.06 Million	0.120x	+177.82%
2023-12-31	NT$5.78 Billion ≈ $182.03 Million	NT$-892.35 Million ≈ $-28.11 Million	-0.154x	-246.22%
2022-12-31	NT$6.54 Billion ≈ $206.20 Million	NT$-291.96 Million ≈ $-9.20 Million	-0.045x	+40.28%
2021-12-31	NT$6.43 Billion ≈ $202.66 Million	NT$-480.52 Million ≈ $-15.14 Million	-0.075x	-121.33%
2020-12-31	NT$6.63 Billion ≈ $208.84 Million	NT$2.32 Billion ≈ $73.15 Million	0.350x	+630.21%
2019-12-31	NT$3.83 Billion ≈ $120.53 Million	NT$-252.72 Million ≈ $-7.96 Million	-0.066x	+79.62%
2018-12-31	NT$1.86 Billion ≈ $58.48 Million	NT$-601.74 Million ≈ $-18.96 Million	-0.324x	-11178.96%
2017-12-31	NT$2.35 Billion ≈ $74.02 Million	NT$6.87 Million ≈ $216.57K	0.003x	+101.17%
2016-12-31	NT$3.09 Billion ≈ $97.51 Million	NT$-773.53 Million ≈ $-24.37 Million	-0.250x	-146.38%
2015-12-31	NT$3.68 Billion ≈ $116.09 Million	NT$-373.82 Million ≈ $-11.78 Million	-0.101x	-8.59%
2014-12-31	NT$4.47 Billion ≈ $140.75 Million	NT$-417.35 Million ≈ $-13.15 Million	-0.093x	+46.82%
2013-12-31	NT$3.24 Billion ≈ $101.99 Million	NT$-568.64 Million ≈ $-17.92 Million	-0.176x	-60.56%
2012-12-31	NT$3.74 Billion ≈ $117.92 Million	NT$-409.48 Million ≈ $-12.90 Million	-0.109x	-34.00%
2011-12-31	NT$3.60 Billion ≈ $113.37 Million	NT$-293.77 Million ≈ $-9.26 Million	-0.082x	-164.23%
2010-12-31	NT$4.06 Billion ≈ $127.99 Million	NT$516.39 Million ≈ $16.27 Million	0.127x	-20.26%
2009-12-31	NT$3.77 Billion ≈ $118.67 Million	NT$600.42 Million ≈ $18.92 Million	0.159x	+472.28%
2008-12-31	NT$3.17 Billion ≈ $99.84 Million	NT$-135.69 Million ≈ $-4.28 Million	-0.043x	-363.61%
2007-12-31	NT$1.92 Billion ≈ $60.63 Million	NT$31.26 Million ≈ $984.86K	0.016x	--

About Adimmune Corp

TW:4142 Taiwan Biotechnology

Market Cap

$235.72 Million

NT$7.48 Billion TWD

Market Cap Rank

#16001 Global

#732 in Taiwan

Share Price

NT$17.75

Change (1 day)

+2.90%

52-Week Range

NT$16.55 - NT$21.55

All Time High

NT$77.19